Trending NewsTrending NewsNASDAQ:QUCY Mainz Biomed (QUCY) Stock Price, News & Analysis $1.30 -0.06 (-4.41%) As of 08/21/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsSEC Filings About Mainz Biomed Stock (NASDAQ:QUCY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Mainz Biomed alerts:Sign Up Key Stats Today's Range$1.27▼$1.3650-Day Range$1.06▼$2.1252-Week Range$0.30▼$4.93Volume1.04 million shsAverage Volume770,260 shsMarket Capitalization$19.06 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany. Read More Mainz Biomed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks33rd Percentile Overall ScoreQUCY MarketRank™: Mainz Biomed scored higher than 33% of companies evaluated by MarketBeat, and ranked 540th out of 661 stocks in the industrials sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.7 / 5Analyst RatingHold Consensus RatingMainz Biomed has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 strong buy rating, no buy ratings, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageMainz Biomed has only been the subject of 3 research reports in the past 90 days.Read more about Mainz Biomed's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Mainz Biomed are expected to grow in the coming year, from ($0.49) to ($0.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mainz Biomed is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mainz Biomed is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMainz Biomed has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted18.04% of the float of Mainz Biomed has been sold short.Short Interest Ratio / Days to CoverMainz Biomed has a short interest ratio ("days to cover") of 4.36.Change versus previous monthShort interest in Mainz Biomed has recently decreased by 8.63%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMainz Biomed does not currently pay a dividend.Dividend GrowthMainz Biomed does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.93 News SentimentMainz Biomed has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Industrials companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Mainz Biomed this week, compared to 4 articles on an average week.Search InterestOnly 4 people have searched for QUCY on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows3 people have added Mainz Biomed to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Mainz Biomed insiders have not sold or bought any company stock.Percentage Held by Insiders3.10% of the stock of Mainz Biomed is held by insiders.Percentage Held by InstitutionsMainz Biomed has minimal institutional ownership at this time.Read more about Mainz Biomed's insider trading history. Receive QUCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mainz Biomed and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QUCY Stock News HeadlinesMainz Biomed Q3 EPS Lifted by Litchfield Hills Research2 hours ago | americanbankingnews.comQuantum Cyber Rejects Threat of Future Publications from Short-Seller Adam Gefvert Demanding Withdrawal of $5.69 Million LawsuitAugust 20 at 4:01 PM | globenewswire.comA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the country entirely - as concerns grow about the next phase of the AI market. One AI insider says investors should reassess their positions before August 31, pointing to a critical shift ahead for tech and AI-related stocks. | TradeSmith (Ad)Quantum Cyber to Participate in Invitation-Only 1640 Society Hamptons Family Office Wealth Forum 2026August 17, 2026 | globenewswire.comLitchfield Hills Research Forecasts Mainz Biomed Q2 EarningsAugust 14, 2026 | americanbankingnews.comQuantum Cyber Unveils the Quantum Photonic Antenna and Publishes Inaugural Technical White Paper Detailing the Quantum Layer of Its Autonomous Defense PlatformAugust 13, 2026 | globenewswire.comMainz Biomed (NASDAQ:QUCY) Upgraded at Litchfield Hills ResearchAugust 13, 2026 | americanbankingnews.comQuantum Cyber Applauds President Trump's Drone Dominance Program and Supply Chain Framework, Reaffirms Commitment to On-Shore U.S. Manufacturing of Autonomous SystemsJuly 29, 2026 | globenewswire.comSee More Headlines QUCY Stock Analysis - Frequently Asked Questions How have QUCY shares performed this year? Mainz Biomed's stock was trading at $0.7374 on March 13, 2026. Since then, QUCY shares have increased by 76.3% and is now trading at $1.30. How do I buy shares of Mainz Biomed? Shares of QUCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today8/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 QUCY's financial health is in the Yellow zone, according to TradeSmith. QUCY has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorIndustrials Industry Aerospace & Defense Sub-IndustryAerospace & Defense Current SymbolNASDAQ:QUCY CIK1874252 Webmainzbiomed.com Phone49 6131 5542860FaxN/AEmployees30Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio5.56 Quick Ratio2.11 Sales & Book Value Annual Sales$537.08 thousand Price / Sales35.49 Cash FlowN/A Price / Cash FlowN/A Book Value$1.38 per share Price / Book0.94Miscellaneous Outstanding Shares14,661,000Free Float14,207,000Market Cap$19.06 million OptionableN/A Beta2.31 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:QUCY) was last updated on 8/22/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour Free Report (Inside)A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | Sponsored23,281 stocks. Only ONE survived.One American energy producer just cleared a screen of 23281 stocks for elite operating profits, double-digit r...Monument Traders Alliance | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSomeone just dumped the biggest gold fund.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mainz Biomed NV Please log in to your account or sign up in order to add this asset to your watchlist. Share Mainz Biomed With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
